Zydus Lifesciences (NSE:ZYDUSLIFE) E10: ₹33.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZYDUSLIFE Zydus Lifesciences Ltd NSE:ZYDUSLIFE
93 GF Score
Price ₹1,131.50
GF Value ₹1,206.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Zydus Lifesciences E10?

Zydus Lifesciences NSE:ZYDUSLIFE -0.33% 93 E10 is ₹33.74 as of Jun. 2026. GuruFocus rates NSE:ZYDUSLIFE with a GF Score™ of 93/100 and a GF Value™ of ₹1,206.11 (Fairly Valued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Zydus Lifesciences's adjusted earnings per share data for the three months ended in Jun. 2026 was ₹9.350. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹33.74 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Zydus Lifesciences's average E10 Growth Rate was 9.20% per year. During the past 3 years, the average E10 Growth Rate was 13.10% per year. During the past 5 years, the average E10 Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Zydus Lifesciences was 16.50% per year. The lowest was 12.70% per year. And the median was 13.80% per year.

As of today (2026-08-17), Zydus Lifesciences's current stock price is ₹1131.50. Zydus Lifesciences's E10 for the quarter that ended in Jun. 2026 was ₹33.74. Zydus Lifesciences's Shiller PE Ratio of today is 33.54.

During the past 13 years, the highest Shiller PE Ratio of Zydus Lifesciences was 46.83. The lowest was 14.42. And the median was 26.82.


Zydus Lifesciences  (NSE:ZYDUSLIFE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Zydus Lifesciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1131.50/33.74
=33.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Zydus Lifesciences was 46.83. The lowest was 14.42. And the median was 26.82.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Zydus Lifesciences E10 Related Terms


Zydus Lifesciences E10 Historical Data

* Premium members only.

The historical data trend for Zydus Lifesciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences E10 Chart

Zydus Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.78 22.82 26.35 29.76 33.03

Zydus Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.91 31.91 32.45 33.03 33.74

NSE:ZYDUSLIFE vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Shiller PE Ratio falls into.


NSE:ZYDUSLIFE
93GF Score
Zydus Lifesciences Ltd NSE:ZYDUSLIFE
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zydus Lifesciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zydus Lifesciences's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.35/167.3573*167.3573
=9.350

Current CPI (Jun. 2026) = 167.3573.

Zydus Lifesciences Quarterly Data

per share eps CPI Adj_EPS
201609 3.710 105.961 5.860
201612 3.160 105.196 5.027
201703 3.770 105.196 5.998
201706 1.350 107.109 2.109
201709 4.920 109.021 7.553
201712 5.310 109.404 8.123
201803 5.770 109.786 8.796
201806 4.500 111.317 6.765
201809 4.080 115.142 5.930
201812 4.990 115.142 7.253
201903 4.500 118.202 6.371
201906 2.970 120.880 4.112
201909 1.050 123.175 1.427
201912 3.650 126.235 4.839
202003 3.820 124.705 5.127
202006 4.430 127.000 5.838
202009 4.996 130.118 6.426
202012 5.150 130.889 6.585
202103 6.630 131.771 8.421
202106 5.740 134.084 7.164
202109 29.330 135.847 36.133
202112 4.890 138.161 5.923
202203 3.880 138.822 4.678
202206 5.060 142.347 5.949
202209 5.150 144.661 5.958
202212 6.150 145.763 7.061
202303 2.940 146.865 3.350
202306 10.740 150.280 11.960
202309 7.910 151.492 8.738
202312 7.800 152.924 8.536
202403 11.690 153.035 12.784
202406 14.110 155.789 15.158
202409 9.060 157.882 9.604
202412 10.170 158.323 10.750
202503 11.640 157.552 12.364
202506 14.580 159.755 15.274
202509 12.510 162.289 12.901
202512 10.360 163.281 10.619
202603 12.650 164.272 12.888
202606 9.350 167.357 9.350

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹33.74 mean?
Zydus Lifesciences (NSE:ZYDUSLIFE) has a E10 of ₹33.74 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zydus Lifesciences and its competitors.
Is Zydus Lifesciences' E10 too high?
Zydus Lifesciences' current E10 is ₹33.74. Overall, Zydus Lifesciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' E10 compare to ZTS?
Zydus Lifesciences' E10 of ₹33.74 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Zydus Lifesciences and its competitors. Zydus Lifesciences's current E10 is ₹33.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (NSE:ZYDUSLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,206.11, compared to a current price of ₹1,131.50 — trading 6.2% below its estimated fair value. The current E10 is ₹33.74. Zydus Lifesciences' overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Zydus Lifesciences (NSE:ZYDUSLIFE), the current E10 is ₹33.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zydus Lifesciences (NSE:ZYDUSLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued. The current stock price of ₹1,131.50 is trading 6.2% below its estimated GF Value™ of ₹1,206.11. GuruFocus considers Zydus Lifesciences to be Fairly Valued.

Key valuation signals for NSE:ZYDUSLIFE:

  • E10: ₹33.74
  • GF Value™: ₹1,206.11 vs. price of ₹1,131.50 (6.2% below fair value)
  • GF Score™: 93/100 with 4 warning signs

No single metric tells the full story. See the NSE:ZYDUSLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zydus Lifesciences Business Description

Other Exchanges 532321:India
Address Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
93GF Score

Get the complete analysis for NSE:ZYDUSLIFE

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,131.50
Price
₹1,206.11
GF Value